Skip to main content

Table 5 Clinical trials of MPs-based cancer therapy

From: Microparticles: biogenesis, characteristics and intervention therapy for cancers in preclinical and clinical research

Disease Drug MPs source Phase, n of patients Objective response rate Refs.
Malignant Pleural
Effusion
MTX Autologous tumor cells Phase 2,
n = 11
90.91% NCT02657460 [91]
Malignant Pleural
Effusion
Cisplatin Tumor cells Phase 2,
n = 6
100% NCT01854866 [85]
Malignant Pleural
Effusion
MTX Tumor cells Phase 2,
n = 32
84.38% ChiCTR-ICR-15006304 [92]
Cholangiocarcinoma MTX Tumor cells Phase 2,
n = 20
100% ChiCTR-OIB-15007589 [93]